Clinical Trials Logo

Genotype clinical trials

View clinical trials related to Genotype.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05916287 Recruiting - Clinical trials for Cardiovascular Diseases

FAMILY INHERITANCE, GENE-GENE AND GENE-ENVIRONMENT INTERACTIONS IN THE FIELD OF CARDIOVASCULAR AND RENAL DISEASES. Fifth Visit of the STANISLAS Cohort

Start date: July 13, 2023
Phase: N/A
Study type: Interventional

The Stanislas Cohort is a monocentric familial longitudinal cohort originally comprised of 1006 families consisting of two parents and at least two biological children and deemed healthy, recruited in 1993-1995 at the Centre for Preventive Medicine of Nancy. This cohort was established with the primary objective of investigating gene-gene and gene-environment interactions in the field of cardiovascular diseases. The 5th visit of the STANISLAS Cohort will allow a better evaluation of the cardiovascular ageing of the population and the transition toward cardiovascular or renal diseases in relation with their genetic profile and environment.

NCT ID: NCT05623059 Recruiting - Asthma Clinical Trials

Evaluate Pharmacokinetics and Safety of Slow Release DHEA

DHEA
Start date: March 3, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a study to look at pharmacokinetic levels of different doses of slow release DHEA in subjects with severe asthma.

NCT ID: NCT03783351 Recruiting - Clinical trials for Acute Coronary Syndrome

Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)

Start date: May 27, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to assess the efficacy and safety of the CYP2C19 genotype guided antiplatelet treatment strategy, using clopidogrel in non-carriers of a CYP2C19*2 or *3 allele and ticagrelor in carriers of a CYP2C19*2 or *3 allele in patients treated with new generation drug eluting stents.

NCT ID: NCT01145196 Recruiting - Retinal Disease Clinical Trials

Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene

Start date: August 23, 2010
Phase:
Study type: Observational

Background: - Plaquenil (hydroxychloroquine) is an anti-inflammatory drug that is used to treat some autoimmune diseases such as lupus and rheumatoid arthritis. This drug can damage the retina by causing a condition called plaquenil-induced retinal toxicity, which may lead to vision loss. However, most people taking plaquenil do not develop this problem. Researchers are interested in studying whether differences in a person s genes explain why some people develop plaquenil-induced retinal toxicity while others do not. Objectives: - To investigate possible correlations between certain genes or genetic mutations and plaquenil-induced retinal toxicity. Eligibility: - Individuals at least 18 years of age who have previously used plaquenil. - Both individuals who have and have not developed plaquenil-induced retinal toxicity will be eligible for this study. Design: - The study requires one or two visits to the National Eye Institute or an outpatient study clinic over a maximum 2-year period. - Participants will provide a personal and family medical history, and will have a full eye examination. - Participants will also provide blood samples for testing. - No treatment will be provided as part of this protocol.

NCT ID: NCT00973037 Recruiting - Breast Neoplasms Clinical Trials

CYP2D6 Genotype on the Clinical Effect of Tamoxifen

ASTRRA-CYP2D6
Start date: March 2009
Phase: N/A
Study type: Observational

The purpose of this study is to investigate the impact of CYP2D6 Genotype on the clinical effects of tamoxifen using with samples from prospective randomized multicenter study(ASTRRA).